INTRODUCTION
Linezolid, an oxazolidinone antibiotic approved for clinical use in 2000, represents the first principally new antibiotic platform that has entered medical practice in more than 30 years. The key pharmacophore of linezolid is a substituted oxazolidinone ring (ring A in Figure 1 ). Linezolid is used for treatment of respiratory tract and skin infections caused by Gram-positive pathogens (Moellering, 2003) .
In addition, linezolid is effective against pathogen strains resistant to many other drugs.
Standard regimens of linezolid do not usually cause adverse reactions, but prolonged treatment with the drug has been associated with side effects that include myelosuppression, resulting in anemia and thrombocytopenia (Kuter and Tillotson, 2001 ). The biochemical mechanism(s) of these side effects is not entirely clear. However, the current evidence is consistent with the hypothesis that inhibition of mitochondrial function is the underlying cause (McKee et al., 2006; Nagiec et al., 2005; Sciotti et al., 2002) .
Oxazolidinone antibiotics inhibit bacterial growth by binding to the ribosomes and interfering with protein synthesis (Shinabarger et al., 1997; Slee et al., 1987) . In spite of considerable effort, neither the mechanism of action of oxazolidinones nor the exact site of the drug action in the translating ribosome are clearly understood. Biochemical studies implicated oxazolidinones in inhibition of such diverse ribosome activities as formation of the initiation complex, synthesis of the first peptide bond, elongation factor G (EF-G)-dependent translocation, termination of translation, and others (Aoki et al., 2002; Bobkova et al., 2003; Burghardt et al., 1998; Matassova et al., 1999; Shinabarger et al., 1997; Swaney et al., 1998a; Thompson et al., 2004) . Some, though not all, of these activities depend on the functions of the ribosomal peptidyl transferase center (PTC).
The results of the in vitro studies of binding of oxazolidinones to their ribosomal target are equally ambiguous. Several of the drug derivatives were shown to bind to the large (50S) ribosomal subunit of the bacterial ribosome and compete with chloramphenicol and lincomycin, known inhibitors of the ribosomal PTC . However, in vitro crosslinking and RNA footprinting suggested interaction of oxazolidinones near the 50S subunit E site located at a considerable distance from the PTC (Matassova et al., 1999) . In addition, some in vitro results suggested that oxazolidinones bind to the small ribosomal subunit (Matassova et al., 1999; Swaney et al., 1998a) .
In contrast, the in vivo data consistently point to the PTC as the main site of oxazolidinone action. Oxazolidinone resistance mutations map at or around the central loop of domain V of 23S rRNA, which constitutes the PTC active site (Kloss et al., 1999; Marshall et al., 2002; Prystowsky et al., 2001; Swaney et al., 1998b; Tsiodras et al., 2001; Xiong et al., 2000) . However, a broad dispersion and species specificity of linezolid resistance mutations in the PTC, combined with the possibility that some of the nucleotide changes may confer resistance allosterically, makes it difficult to use mutational data for the accurate placement of the drug within the ribosome structure.
In this study, we exploited an in vivo crosslinking approach to accurately define the ribosomal binding sites of the oxazolidinone antibiotics in bacterial and eukaryotic cells. The use of new photoreactive derivatives of biologically active oxazolidinones allowed us to triangulate the orientation and model the position of linezolid in the bacterial ribosome. We further demonstrate that the mode of binding of oxazolidinones to the ribosomes of human mitochondria is similar to that in S. aureus bacterial ribosomes and explain both selectivity of the drug action and a possible structural basis for the side effects of the oxazolidinones.
RESULTS
Crosslinking of Oxazolidinones to Ribosomes in S. aureus Cells We used photoaffinity labeling for determining the orientation of oxazolidinone antibiotics within their target site in the ribosomes of living bacteria. S. aureus cells were incubated with radiolabeled biologically active antibiotic derivatives containing a photoreactive chemical group strategically positioned at specific sites in the molecule (Figure 1 ). After brief irradiation with UV light, resulting in crosslinking of the compound to its cellular rRNA target, the site of crosslinking was determined by RNase H mapping and primer extension. In our previous study, we used the oxazolidinone derivative XL1 (Figure 1) , in which the photoreactive aryl-azido group positioned at a considerable distance from the oxazolidinone pharmacophore specifically crosslinked to the conserved nucleotide A2602 located in the peptidyl transferase active site (Colca et al., 2003) . Those data revealed the PTC as the general target of oxazolidinone action, but the orientation of the drug and thus its placement in the ribosome remained unknown.
In order to obtain structural data that allow modeling of the oxazolidinone binding to the ribosome in intact cells, we prepared two new derivatives with the photoreactive azido group positioned at different sites in the molecule. [
3 H]-XL2 contains a photoreactive azido group on the same side of the molecule as XL1, but placed at a shorter distance from the oxazolidinone pharmacophore ( Figure 1B ). Another compound, 125 I-XL3, contains an azido group on the opposite side of the oxazolidinone ring at the pharmacologically critical side chain extending from C5 of ring A. Importantly, both XL2 and XL3 retained biological activity and readily inhibited growth of S. aureus cells (minimal inhibitory concentrations [MIC] of XL2 and XL3 were 0.25 mg/ml and 0.5 mg/ml, respectively; MIC of the clinically approved linezolid, and a related oxazolidinone, eperezolid, is 4 mg/ml for S. aureus). After incubation of S. aureus cells with 0.35-0.7 mg/ml (1-2 mM) of the photoreactive antibiotics and brief irradiation of cells with UV light, radioactivity was incorporated in 23S rRNA, but not in 16S rRNA, suggesting that in living cells oxazolidinone antibiotics specifically bind to the large ribosomal subunit (data not shown). Incorporation of the label in 23S rRNA was dramatically inhibited in the presence of an excess of the noncrosslinkable oxazolidinone competitor eperezolid, confirming specific binding of photoreactive derivatives to the site of action of oxazolidinone drugs in the ribosome. The exact site of crosslinking of XL2 and XL3 was identified by RNase H mapping and primer-extension analysis. The RNase H cleavage of crosslinked 23S rRNA showed that all the radioactivity was associated with a 23S rRNA segment between positions 2275 and 2577 of 23S rRNA (E. coli numbering) (Figure 2A ). Primer extension showed two specific reverse transcriptase stops, indicating that the drug molecule was crosslinked to 23S rRNA positions A2451 and U2506 ( Figure 2B ). The corresponding bands appeared only when cells were irradiated in the presence of photoreactive XL2 but were not seen when XL2 was omitted. The intensity of the bands was significantly diminished when cells were incubated with XL2 in the presence of an excess of the noncrosslinkable competitor eperezolid.
Irradiation of S. aureus cells in the presence of XL3 resulted in incorporation of the label in the same RNase H-generated fragment (positions 2275-2577) as that seen with XL2. Primer extension revealed that XL3 crosslinked to a single 23S rRNA position, G2505 ( Figure 2C ).
Modeling the Site of Oxazolidinone Binding in the Bacterial Ribosome
The UV activation of aryl-azide leads to formation of nitrene, rearrangement of the aromatic ring, and eventual formation of a covalent bond with the RNA or protein chemical groups located in the immediate vicinity of aryl-azide (Shields et al., 1987; Buchmueller et al., 2003) . Such a zero-length crosslinking of the oxazolidinones, which contained azido groups placed at three different locations in the molecule, provided the necessary constraints for placement of the oxazolidinone in the ribosome of living bacterial cells. Because no high-resolution structures of the ribosome from Gram-positive organisms are available in public databases, we chose to model the drug binding by using the 3.5 Å crystallographic structure of the E. coli ribosome (Schuwirth et al., 2005) , which appears as a more attractive template than its counterparts from phenotypically more exotic organisms such as Haloarcula marismortui, Deinococcus radiodurans, or Thermus thermophilus (Ban et al., 2000; Harms et al., 2001; Korostelev et al., 2006; Selmer et al., 2006) . In the bacterial cell, oxazolidinones likely act upon the translating ribosome. This follows from the fact that the drugs crosslink not only to 23S rRNA but also to an RNA species with the electrophoretic mobility of tRNA and to a translation factor, LepA (Colca et al., 2003) (J.R.C., unpublished data with XL2). Peptidyl-tRNA, which is present in the P site of the translating ribosome, may dramatically affect binding of ribosomal antibiotics (Bashan et al., 2003; Hansen et al., 2003; Monro et al., 1969) . With these considerations in mind, we first created an additional ribosome docking model by superposing the peptidyl-tRNA analog from the H. marismortui 50S subunit complexed with CCA-Phe-caproic acid-biotin (CCApcb) into the P site of the vacant E. coli 50S subunit. The conformations of several key nucleotides in the PTC, especially C2601-G2603 and U2585, which are significantly affected by the binding of the P site substrates, were then adjusted to match those of H. marismortui in the complex with the bound P site substrate (Bashan et al., 2003; Hansen et al., 2003) 
(see the Experimental Procedures for details).
The general configuration of the photoreactive compounds in the ribosome was triangulated according to the sites of crosslinks ( Figures 3A-3C ). The contact of azido derivatives of the ring D (XL1) with A2602 and of ring C (XL2) with A2451 and U2506 revealed the orientation of the oxazolidinone in the binding site, running from A2602 (ring D) between the sugars of A2451 and U2506 (ring C) toward the opening of the nascent peptide exit tunnel. This orientation then places ring B between the bases of A2451 and C2452, and stacks the oxazolidinone ring against the face of U2504, with the C5 side chain projecting down into the nascent peptide exit tunnel. Crosslinking of the C5 side chain (XL3) to G2505 suggests that the chain is folded over the oxazolidinone ring on the side of nucleobases 2505 and 2506 ( Figures 3C and 3D) . With a consistent binding mode established for the photoreactive oxazolidinone analogs, linezolid could be easily modeled into the E. coli 70S ribosome crystallographic structure by using a combination of energy minimization and conformational searching. Figure 3D shows the modeled position of linezolid in the bacterial ribosome. The orientation of the central pharmacophore, the oxazolidinone ring, is firmly fixed due to the tight packing of both its side chains against the rRNA residues in the PTC. The placement of the C5 side chain is controlled by the enforced orientation of the oxazolidinone ring, the stereochemistry at C5, and by a hydrogen bond donated from the amide NH to the 5 0 oxygen of G2505. The C5 side-chain amide carbonyl oxygen closely approaches N2 of G2061; however, the geometry of the contact is unfavorable for hydrogen bonding. On the other side of the oxazolidinone pharmacophore, ring B is drawn into a hydrophobic crevice formed by the splayed-out bases A2451 and C2452. This crevice, which was early on proposed to be involved in binding of aromatic amino acid chains (Rodriguez-Fonseca et al., 1995) , contributes to binding of several peptidyl transferase inhibitors, including chloramphenicol, which competes with oxazolidinone for binding Lin et al., 1997; Schlunzen et al., 2001) . The placement of the ring C is dictated largely by its van der Waals interactions with the sugar residues of A2451, C2452, and U2506. The oxazolidinone ring pharmacophore rests in a cradle formed by the nitrogen bases of U2504 and G2061 and the G2505 ribose with the oxazolidinone ring stacked on the uracil base of the U2504 residue, which in E. coli is posttranscriptionally modified to pseudouridine (J) (Conrad et al., 1998) . Mutations of nucleotides that directly interact with linezolid (A2451, C2452, U2504, and G2505) confer resistance in different organisms (Beringer et al., 2005; Kloss et al., 1999; Lobritz et al., 2003; Prystowsky et al., 2001 ) (E.C. Boettger, personal communication). However, G2576, the site of the predominant linezolid resistance mutation in Gram-positive pathogens is not in a direct contact with the drug ( Figure 3D ). Instead, ribosome crystal structures consistently show that the G2576 N1 helps stabilize the positioning of G2505 and U2506 by contributing a hydrogen bond to the nonbridging oxygen of U2506, an interaction that would be lost by the G2576U transversion. Increasing the flexibility of two residues that contact all three rings of linezolid would be expected to reduce binding, as is observed. It is likely that other outer-shell resistance mutations will behave similarly, by either failing to properly stabilize the wild-type oxazolidinone binding ribosome conformation or by actively destabilizing it.
The crosslinking data and the resulting molecular model place linezolid in the A site of the large ribosomal subunit. Ring B occupies space that in the crystallographic structures of the functional ribosomal complexes is used by the tyrosine moiety of puromycin, an A site substrate analog representing the 3 0 end of aminoacyl-tRNA (Bashan et al., 2003; Hansen et al., 2003; Schmeing et al., 2002) ( Figure 3E ). Thus, in the living cell, oxazolidinones should interfere with binding of aminoacyl-tRNA to the ribosomal A site (see Discussion).
Crosslinking of Oxazolidinone to Mitochondrial Ribosomes Some of the known side effects of oxazolidinones are associated with inhibition of mitochondrial protein synthesis (McKee et al., 2006; Nagiec et al., 2005) , which suggests that the compounds may bind to the mitochondrial ribosomes (mitoribosomes) of human cells. Physical characterization as well as cryo-electron microscopy of the mitochondrial ribosome has demonstrated marked differences between the general architecture of the mitoribosome and that of its ancestral bacterial ribosome (Mears et al., 2006; O'Brien et al., 1990; Sharma et al., 2003) . As a result, possible interactions of oxazolidinones with mitoribosomes in human cells could be significantly different from those seen in the bacterial ribosome.
We analyzed crosslinking of the XL2 oxazolidinone derivative to cytoplasmic and mitochondrial ribosomes in human erythroleukemia K562 cells. Cultured human K562 cells were incubated for 1 hr in the presence of 37 mg/ml (100 mM) of XL2 and irradiated with UV light, after which 16S rRNA of the large mitoribosomal subunit and 28S rRNA from the large subunit of cytoplasmic ribosomes were analyzed by primer extension. No oxazolidinone-specific bands were observed when primer extension was carried out on cytoplasmic 28S rRNA ( Figure  2E ), indicating the lack of strong, specific interaction of the compound with the PTC of human cytoplasmic ribosomes. In contrast, primer extension on mitochondrial 16S rRNA showed two bands that appeared only in the sample incubated with the photoreactive antibiotic (Figure 2D ). These bands corresponded to crosslinking of the compound at positions A2451 and U2506, the same positions to which the compound crosslinks in S. aureus ribosomes. The presence of a 5-fold excess of highly active noncrosslinkable competitor PNU-176798 (Sander et al., 2002) (Figure 2D ) or of a 100-fold excess of eperezolid abolished the crosslinking. These results indicate that in mitochondria the photoreactive oxazolidinone binds to the same specific site that is used by active oxazolidinone antibiotics. In agreement with this conclusion, no crosslinking was observed when the photoreactive, but biologically inactive, enantiomer of XL2 was used in the crosslinking experiments (data not shown). The fraction of the mitochondrial ribosomes crosslinked to the antibiotic was estimated by using a modified version of primer-extension analysis ( Figure S1 ). Judging by the relative intensity of cDNA fragments, 3% of mitochondrial ribosomes carried XL2 crosslinked to A2451. Comparison of the crosslink-specific bands in conventional primerextension gels ( Figure 2D ) suggests that XL2 crosslinked to U2506 in $1% of mitochondrial ribosomes.
DISCUSSION
In this work, we used an in vivo crosslinking approach to define the site of action and provide a mechanistic understanding of the medically important oxazolidinone antibiotics in the ribosomes of bacterial and human cells.
A distinct feature of the in vivo crosslinking is that it reveals the site of oxazolidinone action in living cells. This aspect allowed us to overcome many limitations associated with in vitro techniques such as the use of static, nontranslating ribosomes, nonphysiologically high antibiotic concentrations, artificial buffer conditions, etc. Furthermore, with the use of in vivo crosslinking, we were able to gain structural information about interaction of the oxazolidinones with ribosomes of S. aureus, one of the clinically relevant targets of oxazolidinones, as well as with ribosomes of human mitochondria, a focal point of clinical side effects. Though the exact fraction of ribosomes crosslinked to antibiotic was estimated only for mitochondrial ribosomes ( Figure S1 ), comparison of crosslinkspecific bands in the primer-extension gels (Figures 2C and 2D) suggests that the yield of crosslinking in bacteria was comparable to that in mitochondria. Thus, several percent of cellular ribosomes appear to be crosslinked to antibiotic. Given the mild UV-irradiation conditions employed in our experiments, such a high yield of the crosslinked rRNA likely indicates high occupancy of the antibiotic binding site by photoreactive oxazolidinones in the major fraction of bacterial and mitochondrial ribosomes.
The in vivo crosslinking data reveal the ribosomal PTC as the main site of oxazolidinone action: all the 23S rRNA nucleotides that crosslink with oxazolidinones are located in the heart of the PTC. This conclusion is corroborated by mutational data that showed that alterations of nucleotides in the PTC confer linezolid resistance (Kloss et al., 1999; Meka et al., 2004; Prystowsky et al., 2001; Xiong et al., 2000) . However, although resistance mutations may only define the general location of the site of the drug action, zero-length crosslinking of oxazolidinone azido derivatives provide much more precise information about specific contacts between individual functional groups of the compounds and the 23S rRNA nucleotides. This information was critical for molecular modeling of the binding of oxazolidinones to their ribosomal target.
Direct crosslinking of the XL1 derivative to A2602 is possible only when this highly flexible nucleotide assumes a conformation it has in the ribosome with the bound P site tRNA analog . This observation indicates that, in the living cell, oxazolidinones can bind to the ribosome with the occupied P site. However, in contrast to another PTC-targeting antibiotic, sparsomycin, which directly interacts with the peptidyl moiety (Bashan et al., 2003; Hansen et al., 2003) , linezolid does not appear to make a significant contact with the P site substrate analog. We cannot exclude, however, that a longer peptidyl chain on tRNA might come into a direct contact or even clash with the drug, especially if a bulky side chain is attached to the oxazolidinone ring.
The molecular modeling, constrained by the crosslinking data, squarely places oxazolidinones (linezolid) into the A site of the PTC where the drug occupies the space normally taken by the aminoacyl residue of the A sitebound aminoacyl-tRNA ( Figure 3E ). Therefore, oxazolidinones should prevent binding or proper placement of aminoacyl-tRNA in the peptidyl transferase active site. This conclusion is compatible with the observation that oxazolidinones inhibit peptidyl transfer when the A site substrate puromycin is present in limited concentrations (Bobkova et al., 2003; Patel et al., 2001 ), but not when puromycin is present in excess (Kloss et al., 1999; Xiong et al., 2000) . Furthermore, the binding of oxazolidinones in the A site correlates with the recent finding that linezolid, as well as another A site-binding antibiotic, chloramphenicol, affects the accuracy of translation-the activity normally associated with the ribosomal A site (Thompson et al., 2004) .
The present binding model has benefited from availability of multiple photoprobe crosslinks, in comparison to previously published models of oxazolidinone binding. A model relying only on resistance mutation data (Bobkova et al., 2003) essentially has the oxazolidinone interpenetrating as many resistance mutations as possible and invoking reorganization of the nucleotides involved. In that model, the oxazolidinone is oriented in essentially the opposite direction to that dictated by the present photoprobe crosslinking data. A model relying on docking studies informed only by the XL1 photoprobe crosslinking data (Gandhi et al., 2004) provides no obvious explanation for the C5 stereochemistry preference and is inconsistent with the observed XL3 crosslink to G2505. Our model appears to be consistent with a recently disclosed crystal structure of linezolid in the archaeal (H. marismortui) 50S ribosomal subunit (Ippolito et al., 2005) ; however, the presented pictures are not sufficiently detailed to draw definite comparative conclusions, and coordinates are not publicly available.
Some of the in vitro biochemical data, including possible inhibition of binding of initiator tRNA to the ribosome, led to the proposal that oxazolidinones specifically inhibit initiation of translation (Aoki et al., 2002; Patel et al., 2001; Shinabarger et al., 1997) . The view of oxazolidinones as specific inhibitors of translation initiation is hard to reconcile with the antibiotic binding to the A site of the large ribosomal subunit where it can hardly interfere with the placement of initiator fMet-tRNA in the ribosomal P site. Furthermore, inhibitors of translation initiation are expected to cause decomposition of polysomes by allowing postinitiation ribosomes to finish translation but preventing newly initiating ribosomes from entering the elongation cycle. In our hands, treatment of cells with a high concentration of linezolid for 30 min (one doubling time) did not change significantly the shape of the polysome profile (L.X. and A.S.M., unpublished data), arguing against translation initiation being the main target of the drug action. One possible reason for the discrepancy between the in vivo effects of oxazolidinones and in vitro results could be the nonspecific binding of these drugs to the ribosome in the artificial conditions of in vitro experiments .
In human cells, oxazolidinones inhibit mitochondrial protein synthesis (McKee et al., 2006; Nagiec et al., 2005) and thus were expected to interact with the mitoribosomes. With the use of in vivo crosslinking, we were able to pinpoint the site of oxazolidinone action in the ribosomes of human mitochondria. We observed that in the mitoribosome, XL2 crosslinks to exactly the same positions as in the ribosome of bacteria. This result not only provides unequivocal proof of the direct binding of oxazolidinones to mitochondrial ribosomes, but it also shows that the compounds are likely to interact with the same site (A site) to which they bind in bacterial ribosomes. The myelosuppresive side effects associated with prolonged linezolid therapy are consistent with the binding of oxazolidinones to the large subunit of the mitochondrial ribosome and subsequent protein synthesis inhibition.
At the same time, the XL2 derivative did not show specific crosslinking to the large subunit of the cytoplasmic ribosome in the human cells. Though the rRNA nucleotide residues that come into direct contact with the antibiotic in the bacterial ribosome are highly conserved across species, several of the outer-shell nucleotides distinguish human cytoplasmic ribosomes from ribosomes of mitochondria or bacteria (Figure 4) . G2032 of the 23S rRNA in bacteria and 16S rRNA of mammalian mitochondria are replaced by A in the cytoplasmic ribosomes. Similarly C2499 in rRNA of bacteria and mitochondria is replaced by U in cytoplasmic 28S rRNA. Mutations of G2032 or C2499 were shown previously to confer linezolid resistance (Kloss et al., 1999; Thompson et al., 2002; Xiong et al., 2000) . Therefore, the identity of these and possibly several other nucleotides of human 28S rRNA may account for the selectivity of oxazolidinone action.
EXPERIMENTAL PROCEDURES

Reagents and Strains
A linezolid-sensitive clinical isolate of S. aureus (ATCC 29213) was used in the crosslinking experiments. Oxazolidinone derivatives used in the study were synthesized at Pharmacia corporation by using previously published techniques (Barbachyn et al., 1998) . Details of the synthesis will be published elsewhere.
Crosslinking of Photoreactive Oxazolidinones to Their Target in S. aureus Cells
Crosslinking experiments with S. aureus were carried out essentially as described previously with S. aureus strain ATCC 29213 (Colca et al., 2003) . Photoreactive compounds were used at 1-2 mM final concentration (ca. 0.35-0.7 mg/ml) and the competitor, when present, was at 20-200 mM. After incubation of bacteria with the drugs at 37 C for 30 min, the samples were exposed to UV light in a Stratalinker 1800 (Stratagene) (254 nm, 180 mJ). The bacteria were then rinsed with PBS buffer, lysed by incubation with lysostaphin, and total cellular RNA was prepared by phenol, phenol/chloroform, and chloroform extraction followed by precipitation with three volumes of ethanol. The RNA pellets were washed with 1 ml 70% ethanol, dried, and resuspended in water. RNA was analyzed on agarose or denaturing polyacrylamide gels or used for RNase H mapping or primer-extension experiments. After gel electrophoresis, RNA was visualized with ethidium bromide and gels were dried and exposed to Kodak BioMax film with BioMax intensifying screens in order to localize the 125 I crosslinked material. Gels containing material crosslinked with 3 H-XL2
were impregnated with Amplify before exposure to Lightning Plus film (Amersham).
Crosslinking of Photoreactive Oxazolidinones to Their Target in Human Cells
Immediately before each experiment, an appropriate amount of crosslinker was dried in a silicone-treated tube, dissolved in DMSO, and diluted in cell media to 23 final concentration. K562 cells were resuspended in fresh media (RPMI-1640, 10% FBS) at 2 3 10 6 cells per ml. Crosslinking compounds and unlabeled competitors, all dissolved in DMSO, were added to the cells such that the final concentration of DMSO was 1%. After 1 hr incubation at 37 C, the cell suspension was exposed to UV light in a Stratalinker 1800 (Stratagene) (254 nm, 180 mJ). The suspension was transferred to microcentrifuge tubes, washed three times in PBS, and the final pellet was resuspended in 10 mM Tris-HCl (pH 6.8), containing 10 mM KCl and 150 mM MgCl 2 (TKM buffer) and incubated on ice for 5 min followed by disruption with an Ultra TurRax T8 homogenizer (IKA Labortechnik) 3 3 15 s at a setting of 3. An equivalent volume of 2 M sucrose in TKM buffer was added to the tube followed by centrifugation for 3 min at 1000 3 g to pellet cell debris. The supernatant was centrifuged at 8000 3 g for 10 min to pellet the mitochondria. An aliquot of Trizol (0.5 ml) (Invitrogen) was added to the mitochondrial pellet. The pellet was vortexed and incubated at room temperature for 5 min before snap-freezing and storage at À80 C. Total RNA was extracted following the manufacturer's protocol (Invitrogen) and stored in water at À80 C.
RNase H Mapping of the Site of Crosslinking of Photoreactive Compounds to S. aureus 23S rRNA RNase H mapping and primer extension were performed as described previously (Colca et al., 2003) , generally following the previously described protocols (Dontsova et al., 1991; Merryman and Noller, 1998 ).
Molecular Modeling
Molecular modeling was performed with Mosaic2 (J.B. Moon, J.R.B., unpublished data) and Maestro version 7.5, MacroModel version 9.1, and Jaguar version 6.5 (Schrodinger LLC, New York). Molecular mechanics calculations used the AMBER* force field and a distancedependent dielectric constant, 3 = 4r. Force-field parameters were added to allow the C ring anilinic nitrogen, when present, to be pyramidal as found in small molecule crystal structures, rather than planar. Phenyl azide parameters for the photoprobes were developed by using density functional theory calculations (B3LYP/6-31G**) in Jaguar. Working models were built starting from the crystal structure of the E. coli large ribosomal subunit (Protein Data Bank reference code 2AW4) (Schuwirth et al., 2005) , using residues within 30 Å of A2451. After addition of hydrogens, crystallographic waters were allowed to reorient by minimization of hydrogens only but were not further optimized. The canonical oxazolidinone binding pose was first generated by using desazido-XL2 placement in the ribosome informed by the crosslinks, with further refinement by conformational searching in the rigid ribosome using the MCMM method in MacroModel with the meta carbons of ring C loosely tethered (5 ± 2 Å ) to the 2 0 hydroxyls of A2451 and U2506 (the likely nucleophiles). The canonical configuration was further elaborated to full XL2 and XL3 models with similar optimization by conformational searching. For the composite model of XL1 with bound P site CCA-Phe, the CCApcb (CCA-Phe-caproic acid-biotin), magnesium, waters, and residues 2619-2621, 2636-2638, and 2103 (Haloarcula numbering) from the complex of H. marismortui large ribosomal subunit with CCApcb and sparsomycin (Protein Data Bank reference code 1M90) were spliced into the 2AW4 E. coli-based model, followed by truncation of the caproic acid-biotin fragment to acetyl, and restrained energy minimization. After initial oxazolidinone model construction informed by the crosslinks, the oxazolidinone configuration was further refined by conformational searching in the rigid ribosome using the MCMM method in MacroModel, typically with 1000-3000 Monte Carlo iterations.
Previously published oxazolidinone binding models (Bobkova et al., 2003; Gandhi et al., 2004) were carefully replicated by model building in the appropriate crystal structure. Figure 3 , showing oxazolidinone antibiotics modeled in their ribosomal binding site, was prepared using the program PyMOL (DeLano, 2002) .
The molecular coordinates of the model of linezolid binding to the bacterial ribosome are available in the Supplemental Data. 
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